¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ º´Çà) Á¦13Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2020 ±¹Á¦Çмú´ëȸ : 2020-09-03

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ º´Çà) Á¦13Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2020 ±¹Á¦Çмú´ëȸ : 2020-09-03
±³À°ÀÏÀÚ : 2020-09-03
±³À°Àå¼Ò : ¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ ¿¬¼ö±³À° (¿ÀÇÁ¶óÀÎ: µå·¡°ï¾¾Æ¼ ÇѶó·ë ¿Ü)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ º´Çà) Á¦13Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2020 ±¹Á¦Çмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °­ÇØÁø
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : ksmo3@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥,      
Âü¼®¿¹»óÀοø : 1000¸í  
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:00~09:20 Latest findings from ASCO TAPUR study  Richard L. SCHILSKY(ASCO Executive Vice President and Chief Medical Officer USA) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:20~09:40 Initiation of KOSMOS (Korean Precision Medicine Project)  ±èÁöÇö(ºÐ´ç¼­¿ï´ëº´¿ø) 
Åä·Ð 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:40~09:45 Q&A  -(-) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:45~10:00 CancerLINQ, ASCO  Cory D. WIEGERT(ASCO EVP & Chief Executive Officer USA) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:00~10:15 Research application of CancerLINQ  Robert S. MILLER(ASCO CancerLinQ USA) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:15~10:25 Integration of real-world data in oncology field in Korea->Exploration of real-world Korean oncology data (º¯°æ¿äû)  Àå´ë¿µ(ÇѸ²´ëÇб³ÀÇ·á¿ø) 
Åä·Ð 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:25~10:30 Q&A  -(-) 
È޽Ġ09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:30~10:50   () 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:50~11:30 Implementing a comprehensive translational oncology platform in precision medicine: challenges, opportunities, and new directions  Gordon B. MILLS(Knight Cancer Institute USA) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 11:30~11:50 Turning hope into reality: We dream for a better tomorrow with Pembrolizumab (1L NSCLC)  ÀÌ°æ¿ø(°æ»ó´ëÇб³º´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 11:50~12:10 Everything comes to those who challenge: What is the best regimen for 1L R/M HNSCC patients?  ±è¹ü¼®(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 12:10~12:50 MSI- H (High microsatellite instability) : Predictive biomarkers in the era of precision medicine  ±è½ÂÅÂ(»ï¼º¼­¿ïº´¿ø) 
È޽Ġ09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 12:50~13:20   () 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:20~13:30 Neoadjuvant and adjuvant immunotherapy trials in gastric cancer treatment  Çѵ¿¼®(º¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:30~13:40 RECISTing for immunotherapy  ÀÌÈ£¿¬(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:40~13:50 Anti-cancer immune therapy & medical care benefit: Practical issue and unmet need  ±èÀÏȯ(ÇØ¿î´ë¹éº´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:50~14:00 Optimal use of Immunoradiotherpy: Practical issue in radiation oncology  ¼Û½Ã¿­(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:00~14:10 Biomarker testing for cancer immunotherapy  ½ÉÈ¿¼·(¼¼ºê¶õ½ºº´¿ø) 
Åä·Ð 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:10~14:20 Panel Discussion  -(-) 
È޽Ġ09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:20~14:40   () 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:40~15:00 Overcoming resistance to EGFR inhibitor  Helena A. Yu(Memorial Sloan Kettering Cancer Center USA) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 15:00~15:20 Overcoming resistance to ALK inhibitor  ±èµ¿¿Ï(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 15:20~15:40 Biomarkers to immunotherapy  ±èÇý·Ã(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 15:40~16:00 Emerging strategies for immunotherapy combination  Solange PETERS(Lausanne University Hospital Switzerland) 
È޽Ġ09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 16:00~16:20   () 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 16:20~16:40 RNA editing enzyme ADAR1 as an immuno-oncology target  Jin Billy LI(Stanford University USA) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 16:40~17:00 A CRISPR-based screen for the functional assessment of BRCA1 variants  ±è¿ë¼·(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 17:00~17:20 Genetic profiling of acanthotic seborrheic keratosis  ÃÖ¹«¸²(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 17:20~17:40 Werner helicase is a synthetic-lethal target in mismatch repair deficient tumours  Mathew J. GARNETT(Wellcome Sanger Institute UK) 
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 17:40~18:40 Functional genomics approaches to identify targetable dependencies in cancer cells  Mathew J. GARNETT(Wellcome Sanger Institute UK) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ º´Çà) Á¦13Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2020 ±¹Á¦Çмú´ëȸ : 2020-09-03""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÅëÁõÇÐȸ ´ë±¸°æºÏÁöȸ Áý´ãȸ : 2020-09-03
´ÙÀ½±Û ´ëÇÑ ÇǺΰúÇÐȸ ´ë±¸°æºÏÁöºÎ Áý´ãȸ : 2020-09-03
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20745 ¼­¿ï ´ëÇÑÇǺΰúÇÐȸ KSDS 2nd International Congress SEOUL 2024 (1ÀÏÂ÷) : 2024-06-08 0 16 2024-05-27
20744 ¼­¿ï 2024³âµµ Á¦2ȸ °í·Á´ëÇб³ ¾È¾Ïº´¿ø Á¤Çü¿Ü°ú KU-ICL ¿¬¼ö°­Á : 2024-06-08 0 7 2024-05-27
20743 ¼­¿ï ´ëÇÑ°æÃß¿¬±¸È¸ Á¦17ȸ Á¤±âÇмú´ëȸ : 2024-06-08 0 6 2024-05-27
20742 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¾È°ú ±Ý¿äÁý´ãȸ(°©»ó¼±¾Èº´Áõ°ú ÁßÁõ±Ù¹«·ÂÁõ) : 2024-06-07 0 3 2024-05-27
20741 ´ë±¸ ´ëÇѼҾÆû¼Ò³âÁ¤Çü¿Ü°úÇÐȸ - Á¦40ȸ ¿¬·ÊÇмú´ëȸ : 2024-06-07 0 6 2024-05-27
20740 ¼­¿ï 2024³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Çϰ迬¼ö±³À° : 2024-06-07 0 8 2024-05-27
20739 ´ë±¸ ´ëÇÑÁ¤Çü¿Ü°ú ´ë±¸°æºÏÁöȸ - Á¦2ȸ ¿¬¼ö°­Á : 2024-06-07 0 6 2024-05-27
20738 ¿ï»ê ´ëÇѼҾÆû¼Ò³â°úÀÇ»çȸ ¼Ò¾Æ Ç×¹® ³ó¾ç ¹× ¹è²Å Áúȯ : 2024-06-05 0 4 2024-05-27
20737 ¼­¿ï (¿Â¶óÀÎ) Á¦9ȸ ¼Ò¾Æ½ÉÀå ¿È´ÏÅÃÆ® ÄÁÆÛ·±½º : 2024-06-05 0 6 2024-05-27
20736 ¼­¿ï 2024³âµµ ´ëÇÑÁø´Ü°Ë»çÀÇÇаú°³¿øÀÇ»çȸ Çмú´ëȸ : 2024-06-04 0 18 2024-05-27
20735 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-06-03 0 4 2024-05-27
20734 ºÎ»ê ºÎ»ê´ëÇб³º´¿ø ÇǺΰúÇÐÀÇ ÃÖ½ÅÁö°ß(»ö¼ÒÁúȯ Ä¡·á) : 2024-06-03 0 9 2024-05-27
20733 ±¤ÁÖ Á¦ 9Â÷ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ È£³²Áöȸ ¿¬¼ö°­Á : 2024-06-02 0 6 2024-05-27
20732 ¼­¿ï Á¦55Â÷ Ç×¹®Áúȯ¿¬±¸È¸ Áý´ãȸ : 2024-06-02 0 7 2024-05-27
20731 °­¿ø ´ëÇÑ°ñÀýÇÐȸ Á¦6ȸ »óÁö °ñÀý ½ÉÆ÷Áö¾ö : 2024-06-02 0 4 2024-05-27
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷